Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

Abstract Background There is limited real-world evidence that describes patients with newly diagnosed multiple myeloma (NDMM) treated with the bortezomib, lenalidomide, and dexamethasone (VRd) triplet regimen. We evaluated patient characteristics and treatment outcomes among nontransplanted NDMM pat...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Rohan Medhekar, Tao Ran, Alex Z. Fu, Sharmila Patel, Shuchita Kaila
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2022-08-01
Ráidu:	BMC Cancer
Fáttát:	Newly diagnosed multiple myeloma Bortezomib Lenalidomide Dexamethasone Real-world evidence
Liŋkkat:	https://doi.org/10.1186/s12885-022-09980-9
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!